Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Relapsed or Refractory Hodgkin's Lymphoma
NCT00082966Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate up to 3 years, Time to Progression up to 5 years and 1 more. Started Mar 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00082966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082966.